This study examined whether activation of extracellular signal-regulated kinase (ERK) contributes to the increased open-arm time observed in the elevated plus maze (EPM) during opioid withdrawal. We applied SL327, a selective ERK kinase (MEK) inhibitor, to specific limbic areas and examined the effect on EPM behaviors of controls and during naloxone-precipitated morphine withdrawal. We next confirmed that ERK activation increased in limbic areas of mice undergoing naloxone-precipitated morphine withdrawal. Direct injection of SL327 into the amygdala blocked the withdrawal-induced increase in open-arm time; however, injecting SL327 into the septum had no effect. Consistent with these results, both 0.2 and 2 mg/kg naloxone increased ERK activation in the central amygdala of morphine-dependent mice. In drug-naive mice, 2 mg/kg naloxone, but not 0.2 mg/kg, increased ERK activation in the central amygdala. During withdrawal, increased ERK activation was also observed in the lateral septum. In the locus coeruleus, a significant increase was observed only in morphine-dependent mice receiving 2 mg/kg, but not 0.2 mg/kg naloxone. In conclusion, ERK activation in limbic areas is likely involved in both the aversive properties of naloxone and in the affective/emotional symptoms of opioid withdrawal, including mediating EPM behaviors.
Extracellular signal-regulated kinase activation in the amygdala mediates elevated plus maze behavior during opioid withdrawal This study examined whether activation of extracellular signal-regulated kinase (ERK) contributes to the increased open-arm time observed in the elevated plus maze (EPM) during opioid withdrawal. We applied SL327, a selective ERK kinase (MEK) inhibitor, to specific limbic areas and examined the effect on EPM behaviors of controls and during naloxone-precipitated morphine withdrawal. We next confirmed that ERK activation increased in limbic areas of mice undergoing naloxone-precipitated morphine withdrawal. Direct injection of SL327 into the amygdala blocked the withdrawal-induced increase in open-arm time; however, injecting SL327 into the septum had no effect. Consistent with these results, both 0.2 and 2 mg/kg naloxone increased ERK activation in the central amygdala of morphine-dependent mice. In drug-naive mice, 2 mg/kg naloxone, but not 0.2 mg/kg, increased ERK activation in the central amygdala. During withdrawal, increased ERK activation was also observed in the lateral septum. In the locus coeruleus, a significant increase was observed only in morphine-dependent mice receiving 2 mg/kg, but not 0.2 mg/kg naloxone. In conclusion, ERK activation in limbic areas is likely involved in both the aversive properties of naloxone and in the affective/emotional symptoms of opioid withdrawal, including mediating EPM behaviors. 
Introduction
Theories of addiction stipulate that the maintenance of drug abuse, despite the severe consequences, is in part driven by the desire to avoid the precipitation of withdrawal or to escape the withdrawal state (Schulteis and Koob, 1996; Koob et al., 1997) . Like humans, opioid withdrawal in rodents also elicits numerous somatic and affective signs. We recently showed that during both naloxone-precipitated and spontaneous morphine withdrawal, mice exhibit an increase in the time spent in the open arms of the elevated plus maze (EPM) (Hodgson et al., 2008; Buckman et al., 2009) . We hypothesized that this increase in open-arm time might be explained by the different emotionality, motivation, and defensive patterns triggered by withdrawal. Thus, the EPM behaviors of mice undergoing withdrawal may represent a change in their defensive strategies because of an increased motivation to escape. An increase in the motivation to escape might also induce an increase in exploration and/or risk-taking behaviors similar to the behaviors observed in addicts (Hodgson et al., 2008) .
Multiple studies point to the importance of the central amygdala, the extended amygdala and the lateral septum in regulating the affective responses during morphine withdrawal (Aston-Jones et al., 1999; Gracy et al., 2001; Frenois et al., 2002; Watanabe et al., 2002 Watanabe et al., , 2003 Veinante et al., 2003; Hamlin et al., 2004; Jin et al., 2005; Nakagawa et al., 2005) . Moreover, an increase in ERK activation in the central amygdala was recently shown to be involved in cue-induced drug-seeking during opioid withdrawal (Li et al., 2008) . An increase in phospho-ERK (the activated form of ERK) during naloxone-precipitated withdrawal was also observed in the locus coeruleus (LC), solitary tract, hypothalamus (Schulz and Hollt, 1998) , cortex, and striatum (Asensio et al., 2006) , as well as in the spinal cord (Cao et al., 2005 (Cao et al., , 2006 and the heart (Almela et al., 2007) . In the spinal cord, ERK activation contributes to the precipitation of somatic signs (Cao et al., 2005 (Cao et al., , 2006 . In the heart, ERK was shown to contribute to adaptive processes induced by opioid withdrawal, such as c-Fos expression (Almela et al., 2007) .
Given the role of the ERK pathway in withdrawalinduced behaviors, this study examines the involvement of ERK in mediating EPM behavior during withdrawal. Moreover, given the importance of the limbic system in the manifestation of different withdrawal affective signs, we specifically examined the effects of localized ERK inhibition in the amygdala and septum during naloxone-precipitated withdrawal.
Methods

Subjects and drugs
All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by the Institutional Animal Care and Use Committee. Male C57BL/6 mice (9-10 weeks old; Harlan Lab, Houston, Texas, USA) were housed four to five per cage with food and water ad libitum. They were housed in a temperature-controlled vivarium with a 12/12 h light/dark cycle (lights on 07.00 h). Morphine sulfate, naloxone hydrochloride, and SL327 were purchased from Sigma (St. Louis, Missouri, USA). Placebo and 25 mg morphine pellets were supplied by the National Institute on Drug Abuse. Separate mice were used for the immunohistochemical and behavioral analyses.
Stereotaxic manipulation
Cannulae (23 gauge) were inserted bilaterally into the amygdala [position relative to bregma: anteroposterior -1 mm, lateral ± 3.2 mm] and unilaterally into the septum [position relative to bregma: anteroposterior + 1.5 mm, lateral 0 mm] using Kopf 's 1900 Stereotaxic Alignment instrument (Tujunga, California, USA). Mice were given at least 1 week to recover before starting the experiments. To keep the cannulae open and flowing, mice received intracannula saline injections during this week. All intracannula injections were administered using 30-gauge needles inserted 4.2 mm deep for the amygdala and 3 mm deep for the septum. At the end of the experiment, the placement of the cannulae was confirmed by dye injections by an observer blind to the treatments, and any mice with incorrect cannula placement were excluded. We have approximately 90% success rate in the correct placement of bilateral cannulas.
Elevated plus maze
All procedures, except the SL327 and dimethyl sulfoxide (DMSO) injections, were performed in identical manner to our earlier EPM study as described in Hodgson et al. (2008) . Mice were injected twice daily (09.00 and 17.00 h) for 3 consecutive days with saline or increasing doses of morphine [10-40 mg/kg, subcutaneously (s.c.)] for a total of six injections. Specifically, on day 1, the mice were injected with saline or 10 mg/kg morphine. On day 2, mice were injected with saline or 20 mg/kg morphine. On day 3, they were injected with saline or 40 mg/kg morphine. A final dose of 20 mg/kg (s.c.) was administered on day 4. One hour later, the mice were injected with SL327 or DMSO directly into the amygdala or septum. Intracannula injections of SL327 and DMSO were 0.2 ml per side for the amygdala and 0.4 ml for the septum, and were administered over a 10-min period. (ii) total activity, defined as the total number of entries or exits into or out of any arm.
Phospho-extracellular signal-regulated kinase staining
Mice were injected twice daily (09.00 and 17.00 h) for 3 consecutive days with saline or increasing doses of morphine (10-40 mg/kg, s.c.) as described for the EPM study. A final dose was administered on day 4, where mice were injected with saline or 20 mg/kg morphine. Two hours later, the mice were injected s.c. with saline, 0.2 mg/kg naloxone or 2 mg/kg naloxone. Seven minutes after the naloxone injection, they were injected with pentobarbital (100 mg/kg, i.p.) and after another 5 min mice were perfused with 50 ml ice-cold PBS followed by 200 ml of 4% paraformaldehyde. Brains were removed, post-fixed overnight at 41C, cryoprotected in 30% sucrose at 41C for 2 days, and frozen embedded in a Tissue-Tek OCT compound (Sakura Finetek Inc., Torrance, California, USA). The brains were then cryosectioned at 40 mm and stored in PBS containing 0.1% thimerosal at 41C. We performed simultaneous staining on control and treated brain sections using the free-floating method. Briefly, sections were incubated overnight with antibodies against phospho-p42/44 ERK (Cell Signaling Technology, Danvers, Massachusetts, USA) diluted 1 : 300 at 41C. The sections were then washed and incubated with biotin-conjugated anti-rabbit antibodies, followed by ABC enhancement (Vector Lab Inc., Burlingame, California, USA). Staining was revealed using a 3,3 0 -diaminobenzidine kit (Vector Lab Inc., Burlingame, California, USA). USA) and stored using Adobe Photoshop (Adobe Systems Inc., San Jose, California, USA). Particle analysis was performed in regions of interest using National Institutes of Health Image v1.62 as described earlier (Eitan et al., 2003) . For each mouse, three brain areas were analyzedthe central amygdala, lateral septum, and the LC. Areas of interest within each of these sections were determined based on the mouse atlas (Paxinos and Franklin, 2001) . For the central amygdala, we used coronal sections falling between -0.82 and -1.94 mm anteroposterior relative to bregma. In these sections, we analyzed areas identified in the atlas as central amygdaloid nucleus, capsular part, lateral division, medial division, and medial posteroventral part. For the lateral septum, we used coronal sections falling between 1.18 and 0.14 mm anteroposterior relative to bregma. In these sections, we analyzed areas identified in the atlas as lateral septal nucleus, dorsal part, intermediate part, and ventral part. Finally, the sections between -5.34 and -5.68 mm anteroposterior to the bregma were analyzed for the area identified in the atlas as LC. Examples of the areas of interest for each location are marked in Fig. 3 .
In a similar experiment, mice were implanted s.c. with placebo or 25 mg morphine pellets under light isoflurane anesthesia. Three days later, pellets were removed under light anesthesia. An hour later mice were injected with saline or 2 mg/kg naloxone. Brains were then processed for immunohistochemistry and analyzed as described above.
Data analysis
EPM data were analyzed using two-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc comparisons, with condition (control/withdrawal) and treatment (DMSO/SL327) as variables. To analyze the phospho-ERK staining, each brain area of each mouse in the experimental group was normalized to the corresponding staining in the saline control group. The change in staining compared with saline controls was calculated using the following formula: [(experimental value/saline control average) Â 100] -100. Statistical analysis was conducted using two-way ANOVA with pretreatment (placebo/morphine) and treatment (saline/ naloxone) as variables, followed by Bonferroni's post-hoc comparisons.
Results
ERK activation in the amygdala, but not the septum, mediates the increase in open-arm time in the EPM during morphine withdrawal
We first examined the effect of administering SL327, an ERK kinase (MEK) inhibitor, into the amygdala on EPM behaviors in saline-injected control mice and the morphine-dependent mice undergoing withdrawal (Fig. 1) . Two-way ANOVA revealed significant main effects of both withdrawal [F(1,26) = 23.59; P < 0.005] and administration of SL327 [F(1,26) = 13.02; P < 0.025] on open-arm time, but no significant interaction was observed. Bonferroni's post-hoc comparisons revealed a significant increase in open-arm time during naloxoneprecipitated morphine withdrawal (P < 0.01). Injecting SL327 bilaterally (4 mg per side) into the amygdala of mice undergoing withdrawal completely blocked the increase in open-arm time compared with mice injected with vehicle (P < 0.05, Fig. 1a ). The effect of SL327 was not simply because of an effect of overall motor activity. Two-way ANOVA revealed a significant main effect of withdrawal [F(1,26) = 34.48; P < 0.001] on total activity, but no significant effect of SL327 or interaction was observed. Bonferroni's post-hoc comparisons revealed a significant decrease in total activity during naloxoneprecipitated morphine withdrawal in both vehicletreated and SL327-treated mice (P < 0.05) compared with controls. However, there was no significant difference in the total activity between mice undergoing withdrawal that were injected with vehicle and those injected with SL327 (Fig. 1b) . For the drug-naive mice, injecting SL327 into the amygdala had no effect on the time spent in the open arms or total activity (Fig. 1a and  b) . In mice undergoing morphine withdrawal, SL327 (8 mg) injected into the septum did not change the time spent in the open arms or total activity (Fig. 2a and b) .
Naloxone differentially induces an increase in ERK activation in drug-naive and morphine-dependent mice
In rats, increased ERK activation was previously observed in the central, but not basolateral, amygdala during morphine withdrawal (Li et al., 2008) . As mice exhibit species-dependent differences in EPM behaviors during withdrawal (Hodgson et al., 2008) , we next confirmed that indeed in mice there is a comparable increase in ERK activation in the amygdala during morphine withdrawal. In this experiment, we examined ERK activation in drug-naive and morphine-dependent mice receiving low (0.2 mg/kg) and high (2 mg/kg) naloxone doses.
As expected, an increase in ERK activation was observed in the central amygdala. ERK activation was not observed in the basolateral amygdala or any other surrounding areas (data not shown). We also observed increased ERK activation in the lateral septum and LC. An increase in ERK activation was also observed in the bed nucleus of stria terminalis (BNST) in morphine-dependent mice receiving naloxone, but was not quantified (data not shown).
In the central amygdala (Figs 3a and 4a) , two-way ANOVA (n = 10-14) revealed a significant main effect of naloxone treatment [F(2,59) = 57.68; P < 0.001] and a significant interaction between naloxone treatment and morphine pretreatment [F(2,59) = 14.29; P < 0.001]. Bonferroni's post-hoc comparisons revealed that 2 mg/kg naloxone, but not 0.2 mg/kg, significantly increased ERK activation in drug-naive mice (P < 0.001). In morphinedependent mice, a significant decrease was observed in mice receiving saline compared with drug-naive saline controls (P < 0.01). For mice undergoing withdrawal, both 0.2 and 2 mg/kg naloxone significantly increased Blockade of extracellular signal-regulated kinase in the septum has no effect on elevated plus maze behaviors during withdrawal. Mice were injected with increasing doses of morphine for 3 days (10-40 mg/kg, subcutaneously.). On day 4, mice were injected SL327 or dimethyl sulfoxide directly into the septum. Withdrawal was precipitated using 0.2 mg/kg naloxone. No significant effect of SL327 was found. Naloxone administration increases extracellular signal-regulated kinase activation in the brain. Mice were injected with increasing doses of morphine for 3 days (10-40 mg/kg, subcutaneously.). On day 4, withdrawal was precipitated using 2 mg/kg naloxone. A naloxoneinduced increase in extracellular signal-regulated kinase activation was observed in the central amygdala (a), lateral septum (b), and the LC (c). 
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ERK activation in morphine-dependent mice as compared with their drug-naive counterparts (P < 0.001 and P < 0.05, respectively). Moreover, 2 mg/kg naloxone significantly increased ERK activation as compared with 0.2 mg/kg naloxone (P < 0.05).
In the lateral septum (Figs 3b and 4b) , two-way ANOVA (n = 10-14) revealed significant main effects of naloxone treatment [F(2,59) = 14.4; P < 0.001] and morphine pretreatment [F(1,59) = 7.92; P = 0.01], and a significant interaction between naloxone treatment and morphine pretreatment [F(2,59) = 13.95; P < 0.001]. Bonferroni's post-hoc comparisons revealed a significant decrease in ERK activation in morphine-dependent mice receiving saline compared with drug-naive saline controls (P < 0.05). Both 0.2 and 2 mg/kg naloxone significantly increased ERK in morphine-dependent mice as compared with their drug-naive counterparts (P < 0.01). Naloxone did not significantly modulate ERK activation in the lateral septum for drug-naive mice.
In the LC (Figs 3c and 4c) , two-way ANOVA (n = 10-14) revealed a significant main effect of naloxone treatment [F(2,59) = 6.193; P < 0.005] and a significant interaction between naloxone treatment and morphine pretreatment [F(2,59) = 8.672; P < 0.001]. Bonferroni's post-hoc comparisons revealed a significant decrease in ERK activation in morphine-dependent mice receiving saline compared with drug-naive saline controls (P < 0.05). In contrast, 2 mg/kg naloxone significantly increased ERK activation in the LC for morphine-dependent mice as compared with their drug-naive counterparts (P < 0.01). However, 0.2 mg/kg naloxone did not significantly change ERK activation levels in morphine-dependent mice as compared with drug-naive mice.
Similar results were also observed when morphine dependency was established using 25 mg morphine pellets and withdrawal was precipitated with 2 mg/kg naloxone. Namely, increased ERK activation was observed in the central amygdala but not in the basolateral amygdala or other surrounding brain regions (data not shown). Similarly, increased ERK activation was also observed in the lateral septum, BNST, and LC (data not shown).
Discussion
This study shows the involvement of the ERK pathway in the increased open-arm time observed during naloxoneprecipitated morphine withdrawal. Notably, inhibition of ERK in the amygdala blocked the increase in open-arm time, yet inhibiting ERK in the septum had no effect. In addition, increases in phospho-ERK staining (the active form of ERK) were observed in the central amygdala of morphine-dependent mice receiving both 0.2 and 2 mg/kg naloxone. In morphine-dependent mice, the dose required to increase ERK activation in the central amygdala was lower than the dose necessary to precipitate significant jumping behavior (Hodgson et al., 2008 ) -a behavioral measure commonly taken to determine the severity of somatic signs (Iorio et al., 1975) . This low dose, however, is sufficient to precipitate The differential effect of low and high naloxone doses on extracellular signal-regulated kinase activation in drug-naive and morphinedependent mice. Mice were injected with increasing doses of morphine for 3 days (10-40 mg/kg, subcutaneously.). On day 4, withdrawal was precipitated using 0.2 or 2 mg/kg naloxone. (a) central amygdala, (b) lateral septum, and (c) the LC. White bars represent saline treatment; gray bars represent 0.2 mg/kg naloxone treatment; black bars represent 2 mg/kg naloxone treatment. Results are presented as mean ± SEM. (*) indicates a significant difference compared to drug-naive mice receiving saline (P < 0.05); (#) indicates a significant difference compared to drug-naive mice receiving 0.2 mg/kg naloxone (P < 0.05); (}) indicates a significant difference compared to drug-naive mice receiving 2 mg/kg naloxone (P < 0.05); (d) indicates a significant difference compared with morphine-dependent mice receiving saline (P < 0.05).
both the physiological signs of stress from withdrawal, as indicated by significant increases in plasma corticosterone levels, as well as the increase in EPM open-arm time (Hodgson et al., 2008) . Note that although total levels of ERK protein were not measured in our experiments, increases in total protein levels are highly unlikely during the 13-min period.
Previously, correlations were made between the motivational components of naloxone-precipitated morphine withdrawal and the activation of c-Fos in the central amygdala, extended amygdala, and lateral septum (Gracy et al., 2001; Veinante et al., 2003; Hamlin et al., 2004; Jin et al., 2005) . The lateral septum is implicated in the modulation of anxiety through the mu-opioid receptor (Le Merrer et al., 2006) . The central and extended amygdala regulate withdrawal-induced conditioned place aversion (Aston-Jones et al., 1999; Gracy et al., 2001; Jin et al., 2005) and are involved in altered hedonic processing during withdrawal (Harris and Aston-Jones, 2007) . In addition, activation of ERK and cAMP response element-binding protein in the central amygdala is involved in mediating drug-seeking and craving during withdrawal (Li et al., 2008) . However, these brain regions were demonstrated to have little involvement in the precipitation of somatic signs of withdrawal (Maldonado et al., 1992; Nakagawa et al., 2005) .
Consistent with these prior findings, this study implicates ERK activation in the central amygdala in mediating EPM behaviors in mice during withdrawal. It is important to note that in this study, SL327 was injected 1 hour before the precipitation of withdrawal and the EPM test. Although only a very small quantity was administered, we cannot exclude the possibility of some diffusion of SL327 to surroundings areas. Thus, it is possible that the effect on EPM behaviors is because of inhibition of ERK in nearby brain regions. However, consistent with other studies, there were no conditions (i.e. repeated morphine injections, morphine pellets, high and low naloxone doses) in which we observed an increase in phospho-ERK in the areas surrounding the central amygdala. The closest areas in which we observed increased ERK activation were the lateral septum and BNST. Yet, injection of SL327 into the septum had no effect. Thus, it is very likely that the activation of ERK in the central amygdala mediates the effect on EPM behaviors. Nevertheless, we cannot exclude the possibility that changes occurring below the detection threshold in nearby areas are involved in mediating the EPM behaviors during withdrawal.
Naloxone is aversive in both drug-naive (Skoubis et al., 2005) and morphine-dependent mice (Maldonado et al., 2004; Broseta et al., 2005; Shoblock and Maidment, 2006) . However, in drug-naive mice, a high naloxone dose is required to establish significant levels of aversion. In contrast, for morphine-dependent mice, withdrawal precipitation even by lower naloxone doses is sufficient to produce a significant emotional reaction. Just as high doses are required to induce aversion in opioid-naive mice, drug-naive mice also require 2 mg/kg naloxone, not just 0.2 mg/kg, to increase ERK activation in the central amygdala. Thus, we hypothesize that the activation of ERK in limbic areas is most likely also involved in the aversive properties of naloxone. The central amygdala is known to have high tonic levels of enkephalin and other endogenous opioid peptides (Mansour et al., 1993; Chieng et al., 2006; Marchant et al., 2007; Poulin et al., 2008) . Given that drug-naive mice lacking preproenkephalin do not exhibit increased ERK activation in the central amygdala (Eitan et al., 2002) , it supports the hypothesis that naloxone increases ERK activation through inhibition of tonic signaling of endogenous opioid peptides. Similar to ERK, an increase of c-Fos in the central amygdala was observed in drug-naive rats after naloxone administration (Gestreau et al., 2000) .
As mentioned above, increased ERK activation was observed in the central amygdala of drug-naive mice administered with 2 mg/kg naloxone, but not 0.2 mg/kg naloxone. However, drug-naive mice did not exhibit a significant increase in open-arm time even when administered 10 mg/kg naloxone (Hodgson et al., 2008) . Therefore, it is very unlikely that the differences in EPM behaviors between drug-naive and morphine-dependent mice receiving naloxone can be explained solely by different levels of ERK activation. This leads to the conclusion that the increase in ERK activation is necessary to drive the increased EPM open-arm time during withdrawal. However, the lack of naloxoneinduced increases in EPM open-arm time in drug-naive mice suggests that other signaling cascades are required in addition to ERK activation.
This study also showed increased ERK activation in the LC during opioid withdrawal. This is consistent with a previous study that observed an increase in phospho-ERK staining in the LC (Schulz and Hollt, 1998) . In contrast to the limbic areas, increased ERK activation in the LC was observed only in morphine-dependent mice receiving the higher naloxone dose -a dose needed to precipitate significant jumping behavior (Hodgson et al., 2008) . The LC was suggested to be essential for the development of morphine dependence and the precipitation of withdrawal signs, especially the physical symptoms (Aghajanian, 1978; Crawley et al., 1979; Maldonado et al., 1992) . Specifically, inhibition of adrenergic tone, mediated by GIRK2 and GIRK3, was suggested to be required for the development of dependence (Cruz et al., 2008) . Likewise, various receptors and signaling molecules in the LC were shown to be involved in the precipitation of withdrawal's somatic signs. Examples include a-2 adrenoceptors (Aghajanian, 1982; Engberg et al., 1982) , g-aminobutyric acid receptor (Mirzaii-Dizgah et al., 2008) , glutamate transporters Ozawa et al., 2004) , and the cAMP pathway, including adenylyl cyclases 1 and 8 and cAMP response element-binding protein (Lane-Ladd et al., 1997; Valverde et al., 2004; Han et al., 2006; Oh et al., 2007; Zachariou et al., 2008) . However, the role of the LC in the precipitation of somatic withdrawal signs remains somewhat debatable, given that lesioning of noradrenergic terminals arising from the LC does not inhibit the precipitation of physical symptoms of opioid withdrawal (Chieng and Christie, 1995) .
In this study, we also observed a decreased ERK activation in the central amygdala, lateral septum, and LC of morphine-dependent mice receiving saline (i.e. in which withdrawal was not precipitated with naloxone). We previously observed decreased ERK activation in the central amygdala 30 min after acute or repeated morphine administration (Eitan et al., 2003) . This was the only brain region in which we did not observe the development of tolerance for ERK modulation after repeated morphine administration, although antinociceptive tolerance was observed (Eitan et al., 2003) . Thus, the decreased ERK activation in the central amygdala is most likely a persistent morphine effect that is already observed at 30 min post-morphine and lasts for at least 2 h. This is unlikely because of spontaneous withdrawal, given that the half-life of morphine (Kalvass et al., 2007) requires a longer duration before withdrawal spontaneously precipitates.
For the LC, we previously observed that acute morphine administration produces an increase in ERK activation (Eitan et al., 2003) . However, after repeated morphine administration, tolerance for ERK activation developed; namely, we did not observe an increase or a decrease in ERK activation 30 min post-morphine in mice receiving repeated morphine administration, as compared with controls (Eitan et al., 2003) . In this study, morphinedependent mice showed a decrease in ERK activation at 2 h post-morphine. This decreased ERK activation might represent a delayed adaptive response to a morphine challenge in morphine-dependent mice. Such opposite responses are known to emerge upon cessation of prolonged administration of opioids. These opponent processes in many cases counteract the acute effects of opioids (e.g. hyperalgesia vs. antinociception) and can contribute to the development of tolerance and physical dependence (Bryant et al., 2005) . Thus, the decrease in ERK activation may represent one of several cellular opponent processes. Interestingly, this cellular event parallels the opioid-induced hyperalgesia (behavioral rebound) observed at the same time in morphine-tolerant mice (Eitan et al., 2003) .
Although opiates are commonly used for pain management, the neuroplastic mechanisms underlying their adaptive processes remain somewhat elusive. The purpose of this study was to examine the involvement of the ERK pathway in EPM behaviors of mice undergoing opioid withdrawal. We focused on the ERK pathway because it plays an important role in synaptic plasticity, and has been implicated in the chronic adaptations to opioids. We observed an increase in ERK activation at the onset of morphine withdrawal. This increase was observed in brain areas previously implicated in mediating the emotional response to withdrawal. Finally, we found that ERK signaling is necessary for mediating the withdrawal-induced increase in EPM open-arm time. Future studies will examine the receptor mechanisms involved, as well as other brain pathways and signaling cascades that are important in driving behavioral adaptations during drug withdrawal.
